Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: ABBV stock price vs MKL: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at MKL's multiple
Needs Annual EPS, MKL P/E.
Implied fair value · at ABBV's multiple
Needs Annual EPS, ABBV P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Higher is better
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
AbbVie Inc. · implied price per share
Reporting currency could not be verified.
MARKEL GROUP INC. · implied price per share
Reporting currency could not be verified.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
ABBV · not enough data.
MKL · not enough data.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Pfizer Inc.
ABBV vs PFE
Johnson & Johnson
ABBV vs JNJ
Merck & Co., Inc.
ABBV vs MRK
Eli Lilly and Company
ABBV vs LLY
Amgen Inc.
ABBV vs AMGN
Gilead Sciences, Inc.
ABBV vs GILD
TRAVELERS COMPANIES, INC.
ABBV vs TRV
ALLSTATE CORP
ABBV vs ALL
PROGRESSIVE CORP/OH/
ABBV vs PGR
Chubb Ltd
ABBV vs CB
EVEREST GROUP, LTD.
ABBV vs EG
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe ABBV can sustain a very high earnings multiple despite only moderate quality scores and higher leverage, then holding or buying may be justified; otherwise, the data favor avoiding ABBV on relative valuation because MKL is far cheaper on every major trading multiple and stronger on ROIC.
ABBV trades at a large premium to MKL on both earnings and sales bases, with the provided P/E-implied price of $25.52 implying -88.6% downside from the current $224.77 price. The gap is hard to justify from the data because ABBV is more expensive on P/E, P/S, EV/EBITDA, and EV/Revenue while MKL also shows stronger ROIC.
Supporting Metrics
